Showing results (2161-2170 of 2,307) with videos related to
Sort By:
Pageof 231
Science Immunology|August 15, 2025
Combined Flt3L and CD40 agonism restores dendritic cell-driven T cell immunity in pancreatic cancerGraham D Hogg, Alyssa G Weinstein, Natalie L Kingston, et al.Cancer Cell|August 15, 2023
Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-originWen-Wei Liang, Rita Jui-Hsien Lu, Reyka G Jayasinghe, et al.Cell|January 5, 2024
Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategiesQian Liu, Jing Zhang, Chenchen Guo, et al.Nature Methods|October 15, 2013
DGIdb: mining the druggable genomeMalachi Griffith, Obi L Griffith, Adam C Coffman, et al.Cancer Letters|April 8, 2026
Survival Benefit of Allogeneic HSCT in CMML patients During the Molecular Stratification EraRui Ma, Jin Zhang, Mei-Xiang Zhang, et al.The Journal of Experimental Medicine|March 23, 2023
Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapyChong Zuo, John M Baer, Brett L Knolhoff, et al.Nature|December 10, 2014
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaTerrence N Wong, Giridharan Ramsingh, Andrew L Young, et al.The Journal of Clinical Investigation|December 28, 2018
Long noncoding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXNYan-Wei Hu, Feng-Xia Guo, Yuan-Jun Xu, et al.Molecular & Cellular Proteomics : MCP|June 15, 2019
Regulated Phosphosignaling Associated with Breast Cancer Subtypes and DruggabilityKuan-Lin Huang, Yige Wu, Tina Primeau, et al.Nature|May 28, 2025
Light-triggered regionally controlled n-doping of organic semiconductorsXin-Yi Wang, Yi-Fan Ding, Xiao-Yan Zhang, et al.Pageof 231